Home › Research › Drug development
Antiamyloid treatment for dementia: concerns outweigh hopes
Flicker L.. Current opinion in psychiatry, 2025-06-09
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Purpose of review To review the association between Alzheimer pathology and dementia and the role of mAbs targeting amyloid in the treatment of people with dementia and mild cognitive impairment. Recent findings There is an association, but Alzheimer pathology explains less than 40% of the attributable risk of dementia when other pathologies such as vascular, Lewy Body and TDP-43 are accounted. Recent trials of passive immunization with MABs, including Aducanumab Lecanemab and Donanemab, have demonstrated some benefits but the effects are small in size and may be due to bias.
What this study adds
Evidence grade: Low
This is a narrative review. This review states that recent trials of antibodies including aducanumab, lecanemab and donanemab showed some benefits, but the effects are small and may be due to bias. It notes that amyloid-related imaging abnormalities are common and potentially serious, and that Alzheimer pathology explains less than 40% of the attributable risk of dementia.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Flicker, L. (2025). Antiamyloid treatment for dementia: concerns outweigh hopes. Current opinion in psychiatry. https://doi.org/10.1097/yco.0000000000001021
Vancouver
Flicker L. Antiamyloid treatment for dementia: concerns outweigh hopes. Current opinion in psychiatry. 2025. doi:10.1097/yco.0000000000001021. PMID: 40511512.
BibTeX
@article{flicker2025-40511512,
author = {Flicker, L.},
title = {{Antiamyloid treatment for dementia: concerns outweigh hopes}},
journal = {Current opinion in psychiatry},
year = {2025},
doi = {10.1097/yco.0000000000001021},
pmid = {40511512},
url = {https://doi.org/10.1097/yco.0000000000001021}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Recent findings There is an association, but Alzheimer pathology explains less than 40% of the attributable risk of dementia when other pathologies such as vascular, Lewy Body and TDP-43 are accounted.
- Recent trials of passive immunization with MABs, including Aducanumab Lecanemab and Donanemab, have demonstrated some benefits but the effects are small in size and may be due to bias.
- The side effect of amyloid-related imaging abnormalities (ARIA) is common and potentially serious.
- The costs of assessments for treatment and actual treatment costs are large compared with potentially modest benefits.
Why it matters
This review states that recent trials of antibodies including aducanumab, lecanemab and donanemab showed some benefits, but the effects are small and may be due to bias. It notes that amyloid-related imaging abnormalities are common and potentially serious, and that Alzheimer pathology explains less than 40% of the attributable risk of dementia.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current opinion in psychiatry) |
| Journal's citation record | 1 / 4 | Current Opinion in Psychiatry: journal h-index 141 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Leon A Flicker: h-index 93 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Western Australia: institution h-index 1,026 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40511512) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Related studies in Drug development from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.